Figure 1.

Potency of prostate cancer cell growth inhibition of the 38 FDA-approved or clinically used compounds emerging from the primary screen. Shown are results from the secondary screen for these compounds. The 38 drugs are categorized as known anti-neoplastic or non-antineoplastic drugs based on their known clinical indications. The IC₅₀ determined for each drug and each cell line in the secondary screen are color scaled as shown. Non-antineoplastic drugs are arranged by order of mean potency across the six prostate cancer cell lines.